ASCO star, backed by billionaires, goes to Astellas in $1.4 billion buyout
Among the galaxy of oncology players that showed up at ASCO last summer to boast about their progress or lay claims to bright futures, few delivered the real goods as well as overnight star Ganymed.
The little-known German biotech grabbed the spotlight at the big conference with IMAB362, which wrapped a mid-stage study showing it “can significantly extend median survival when added to standard chemotherapy—13.2 months vs. 8.4 months—for patients with advanced gastric cancer.” This therapy is the first drug that targets a protein called claudin18.2, and subjects in the 161-patient study with the highest levels of claudin18.2 had a significantly longer median overall survival rate: 16.7 months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
